title: What about the risk of thrombosis with bioresorbable scaffolds?
abstract: Bioresorbable scaffolds promise to counteract late thrombosis by the absence of residual foreign material over time and the restoration of functional endothelial coverage. However, although currently available data are controversial, initial post-marketing studies have raised some concerns about the putative increased early thrombogenicity of bioresorbable scaffolds as compared to currently available second-generation drug-eluting stents. This article focuses on incidence rates, putative mechanisms and prevention strategies of scaffold thrombosis.
authors.affiliation: Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Capodanno
authors.forename: Michael
authors.initials: M
authors.lastname: Joner
authors.forename: Marco
authors.initials: M
authors.lastname: Zimarino
mesh_terms: D020341:Absorbable Implants; D003324:Coronary Artery Disease / Q000601:surgery*; D003328:Coronary Thrombosis / Q000453:epidemiology* / Q000517:prevention & control; D054855:Drug-Eluting Stents; D004868:Equipment Failure / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation* / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology* / Q000517:prevention & control; D012307:Risk Factors; D054457:Tissue Scaffolds
chemical_list: D010975:Platelet Aggregation Inhibitors